Freeform Search

Database: US Pre-Grant Publication Full-Text Database; US Patents Full-Text Database; US OCR Full-Text Database; EPO Abstracts Database; JPO Abstracts Database; Derwent World Patents Index; IBM Technical Disclosure Bulletins

Term: L23 not l22

Display: 200 **Documents in Display Format:** - **Starting with Number** 1

Generate: ○ **Hit List** ◉ **Hit Count** ○ **Side by Side** ○ **Image**

Search | Clear | Interrupt

Search History

DATE: Thursday, October 05, 2006 Purge Queries | Printable Copy | Create Case

Set Name side by side	Query	Hit Count	Set Name result set
DB=PGPB,USPT,EPAB,JPAB,DWPI; PLUR=YES; OP=OR			
L24	L23 not l22	65	L24
L23	sucralose same tablet and dextrose	87	L23
L22	L21 and dextrose	22	L22
L21	sucralose same tablet same (soft or chewable or chewing or disintegrat$4)	41	L21
L20	sucralose same tablet	140	L20
L19	L18 and dextrose	17	L19
L18	(fat or oil or lipid or triglyceride or glyceride) adj2 free same tablet	54	L18
L17	(fat or oil or lipid or triglyceride or glyceride) adj3 free adj5 tablet	2	L17
L16	(fat or oil or lipid or triglyceride or glyceride) adj3 free same tablet	61	L16
L15	(fat or oil or lipid or triglyceride or glyceride) adj3 free same soft adj2 tablet	0	L15
L14	chewable adj2 tablet same (sugar or non-sweet$4 or sweet) adj3 free	18	L14
L13	(fat or oil or lipid or triglyceride or glyceride) adj3 free same chewable adj2 tablet	3	L13
L12	(fat or oil or lipid or triglyceride or glyceride) adj3 free and chewable adj2 tablet same (sugar or non-sweet$4 or sweet) adj3 free	2	L12

L11	(fat or oil or lipid or triglyceride or glyceride) adj3 free same chewable adj2 tablet and (sugar or non-sweet$4 or sweet) adj3 free	2	L11
L10	(fat or oil or lipid or triglyceride or glyceride) adj3 free same tablet and (sugar or non-sweet$4 or sweet) adj3 free same tablet	6	L10
L9	(fat or oil or lipid or triglyceride or glyceride) adj3 free and (sugar or non-sweet$4 or sweet) adj3 free same tablet	9	L9
L8	(fat or oil or lipid or triglyceride or glyceride) adj3 free adj5 (sugar or non-sweet$4 or sweet) same tablet	0	L8
DB=PGPB,USPT; PLUR=YES; OP=OR			
L7	6596311.pn.	1	L7
L6	luber-joseph.in.	11	L6
L5	luber-j.in.	0	L5
L4	bunick-frank.in.	1	L4
L3	L2	45	L3
DB=PGPB,USPT,EPAB,JPAB,DWPI; PLUR=YES; OP=OR			
L2	bunick.in.	131	L2
L1	bunick-f.in.	1	L1

END OF SEARCH HISTORY

=> d l1 ibib kwic

L1 ANSWER 1 OF 23 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:1193308 CAPLUS
DOCUMENT NUMBER: 143:466159
TITLE: Controlled release mucoadhesive matrix formulation containing tolterodine and a process for its preparation
INVENTOR(S): Durga Maheswari, Parvataneni; Appalaswamy Naidu, Rongala; Podile, Khadgapathi; Venkaiah Chowdary, Nannapaneni
PATENT ASSIGNEE(S): Natco Pharma Limited, India
SOURCE: PCT Int. Appl., 36 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005105036	A1	20051110	WO 2005-IN99	20050404

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: IN 2004-CH393 A 20040428
REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

AB Controlled release oral pharmaceutical mucoadhesive matrix formulation containing a therapeutically effective amount of tolterodine or its pharmaceutically acceptable salts, prodrugs and metabolites thereof dispersed in a rate controlling polymeric matrix comprising (1) a pH independent gelling polymer, such as polyethylene oxide, (2) pH dependent gelling polymer, such as sodium CM-cellulose (3) a film coating polymer component, such as Eudragit RS100 and other conventional tablet functional excipients. The formulation such as tablets or minitablets in capsules of the present invention relates to a 24 h controlled release dosage form useful for the treatment of urge incontinence and other symptoms of unstable or overactive urinary bladder. The invention also relates to a process for the preparation of controlled release mucoadhesive matrix formulation containing tolterodine in a tablet or mini tablets in capsule dosage form. For example, controlled-release mucoadhesive matrix tablets were prepared by wet granulation of tolterodine tartrate 2.0, polyethylene oxide-18 NF 7.0, sodium CM-cellulose 3.0, lactose anhydrous 20.0, microcryst. cellulose 51.8, polyvinylpyrrolidone K-30 5.0, Eudragit RS 100 10.0, iso-Pr alc. 72, and acetone 48, granules obtained were dried, lubricated

with colloidal silica 0.1, talc 0.1, and magnesium stearate 1.0 mg, resp., and compressed into core tablets. Eudragit L 100-55 3.0 was added to a mixture of iso-Pr alc. 25.6 and acetone 37.8, followed by tri-Et citrate 0.5 mg, resp., and the solution obtained was used as a barrier coating for core tablets.

IT Polysaccharides, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(acidic; preparation of controlled-release polymeric mucoadhesive matrix containing tolterodine for tablets or minitablets)

IT Drug delivery systems
(bioadhesive, mucoadhesive; preparation of controlled-release polymeric mucoadhesive matrix containing tolterodine for tablets or minitablets)

IT Drug delivery systems
(capsules, controlled-release, minitablets-containing; preparation of controlled-release polymeric mucoadhesive matrix containing tolterodine for tablets or minitablets)

IT Alcohols, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(fatty; preparation of controlled-release polymeric mucoadhesive matrix containing tolterodine for tablets or minitablets)

IT Cereal (grain)
(hydrolyzed, solids; preparation of controlled-release polymeric mucoadhesive matrix containing tolterodine for tablets or minitablets)

IT Bladder, disease
(incontinence, treatment of; preparation of controlled-release polymeric mucoadhesive matrix containing tolterodine for tablets or minitablets)

IT Polyesters, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(lactic acid-based; preparation of controlled-release polymeric mucoadhesive matrix containing tolterodine for tablets or minitablets)

IT Polymers, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(matrix; preparation of controlled-release polymeric mucoadhesive matrix containing tolterodine for tablets or minitablets)

IT Drug delivery systems
(oral, controlled-release; preparation of controlled-release polymeric mucoadhesive matrix containing tolterodine for tablets or minitablets)

IT Bladder, disease
(overactive bladder, treatment of; preparation of controlled-release polymeric mucoadhesive matrix containing tolterodine for tablets or minitablets)

IT Coating materials
(polymer film; preparation of controlled-release polymeric mucoadhesive matrix containing tolterodine for tablets or minitablets)

IT Dissolution
Gelation agents
Gums and Mucilages
Plasticizers
(preparation of controlled-release polymeric mucoadhesive matrix containing tolterodine for tablets or minitablets)

IT Adhesins
Agglutinins and Lectins
Bentonite, biological studies

Biopolymers
Carbohydrates, biological studies
Clays, biological studies
Gelatins, biological studies
Glycoproteins
Hydrocarbon oils
Kaolin, biological studies
Polyesters, biological studies
Polyoxyalkylenes, biological studies
Smectite-group minerals
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation of controlled-release polymeric mucoadhesive matrix containing tolterodine for tablets or minitablets)

IT Drug delivery systems
(tablets, controlled-release; preparation of controlled-release polymeric mucoadhesive matrix containing tolterodine for tablets or minitablets)

IT Fats and Glyceridic oils, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(vegetable, hydrogenated; preparation of controlled-release polymeric mucoadhesive matrix containing tolterodine for tablets or minitablets)

IT Granulation
(wet; preparation of controlled-release polymeric mucoadhesive matrix containing
tolterodine for tablets or minitablets)

IT 9003-01-4D, crosslinked
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Carbopol; preparation of controlled-release polymeric mucoadhesive matrix containing tolterodine for tablets or minitablets)

IT 9003-39-8D, crosslinked
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Crospovidone; preparation of controlled-release polymeric mucoadhesive matrix containing tolterodine for tablets or minitablets)

IT 9010-88-2, Eudragit NE 30D
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Eudragit NE 50D; preparation of controlled-release polymeric mucoadhesive matrix containing tolterodine for tablets or minitablets)

IT 9050-36-6, Maltodextrin
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Mor-Rex; preparation of controlled-release polymeric mucoadhesive matrix containing tolterodine for tablets or minitablets)

IT 7631-86-9, Silica, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(colloidal; preparation of controlled-release polymeric mucoadhesive matrix containing tolterodine for tablets or minitablets)

IT 9004-34-6, Cellulose, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(microcryst.; preparation of controlled-release polymeric mucoadhesive matrix containing tolterodine for tablets or minitablets)

IT 124937-51-5, Tolterodine 124937-52-6, Tolterodine tartrate
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation of controlled-release polymeric mucoadhesive matrix containing tolterodine for tablets or minitablets)

IT 50-70-4, Sorbitol, biological studies 50-99-7, D-Glucose, biological studies 56-40-6, Glycine, biological studies 57-11-4, Stearic acid,

biological studies 57-48-7, Fructose, biological studies 57-50-1, Sucrose, biological studies 69-65-8, D-Mannitol 77-89-4, Acetyl triethyl citrate 77-90-7, Acetyl tributyl citrate 79-41-4D, Methacrylic acid, derivs., polymers 84-66-2, Diethyl phthalate 84-74-2, Dibutyl phthalate 87-89-8, Inositol 88-99-3, Phthalic acid, biological studies 102-76-1, Triacetin 108-32-7, Propylene carbonate 109-43-3, Dibutyl sebacate 112-92-5, Stearyl alcohol 117-81-7, Dioctyl phthalate 134-03-2, Sodium ascorbate 471-34-1, Calcium carbonate, biological studies 557-04-0, Magnesium stearate 557-05-1, Zinc stearate 585-86-4, Lactitol 1327-43-1, Magnesium aluminum silicate 1344-95-2, Calcium silicate 1592-23-0, Calcium stearate 4070-80-8, Sodium stearyl fumarate 7789-77-7, Dibasic calcium phosphate dihydrate 9000-01-5, Acacia gum 9000-07-1, Carrageenan 9000-11-7, Carboxymethyl cellulose 9000-30-0, Guar gum 9000-36-6, Karaya gum 9000-40-2, Locust bean gum 9000-65-1, Tragacanth gum 9000-69-5, Pectin 9002-18-0, Agar 9002-88-4D, Polyethylene, alkyl ethers 9003-01-4, Poly(acrylic acid) 9003-39-8, Polyvinylpyrrolidone 9004-32-4, Sodium CM-cellulose 9004-38-0, CAP 9004-53-9, Dextrin 9004-57-3, Ethyl cellulose 9004-61-9, Hyaluronic acid 9004-62-0, Hydroxyethyl cellulose 9004-64-2, Hydroxypropyl cellulose 9004-65-3, Hypromellose 9004-67-5, Methyl cellulose 9005-25-8, Starch, biological studies 9005-32-7, Alginic acid 9005-38-3, Sodium alginate 9005-65-6, Polysorbate 80 9005-82-7, Amylose 9012-76-4, Chitosan 9050-31-1, HPMCP 9063-38-1, Sodium starch glycolate 10101-41-4, Calcium sulfate dihydrate 12705-30-5, Celutab 13463-67-7, Titanium dioxide, biological studies 14807-96-6, Talc, biological studies 18662-40-3, Calcium sulfate monohydrate 25086-15-1, Eudragit S 100 25212-88-8, Eudragit L 100-55 25322-68-3, Polyethylene oxide 25496-72-4, Glyceryl monooleate 26009-03-0, Poly(glycolic acid) 26023-30-3, Poly[oxy(1-methyl-2-oxo-1,2-ethanediyl)] 26100-51-6, Poly(DL-lactic acid) 26124-68-5, Poly(glycolic acid) 26936-24-3, Eudragit FS 30D 31566-31-1, Glyceryl monostearate 33434-24-1, Eudragit RS 100 36653-82-4, Cetyl alcohol 39301-46-7, Calcium pectinate 53237-50-6 66828-18-0, Dextrate 71138-97-1, HPMCAS 74811-65-7, Croscarmellose sodium 77538-19-3, Glyceryl behenate 77938-63-7, Dextrose monohydrate 139061-06-6, Calcium lactate trihydrate 147335-38-4, Eudragit NE 40D 178806-61-6, Eudragit RLPO 476312-12-6, Carbopol 71G 869094-48-4, Maltrons

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation of controlled-release polymeric mucoadhesive matrix containing tolterodine for tablets or minitablets)

=> d l1 ibib kwic 1-
YOU HAVE REQUESTED DATA FROM 23 ANSWERS - CONTINUE? Y/(N):y

L1 ANSWER 1 OF 23 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:1193308 CAPLUS
DOCUMENT NUMBER: 143:466159
TITLE: Controlled release mucoadhesive matrix formulation containing tolterodine and a process for its preparation
INVENTOR(S): Durga Maheswari, Parvataneni; Appalaswamy Naidu, Rongala; Podile, Khadgapathi; Venkaiah Chowdary, Nannapaneni
PATENT ASSIGNEE(S): Natco Pharma Limited, India
SOURCE: PCT Int. Appl., 36 pp.

lc

CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005105036	A1	20051110	WO 2005-IN99	20050404

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: IN 2004-CH393 A 20040428
REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

AB Controlled release oral pharmaceutical mucoadhesive matrix formulation containing a therapeutically effective amount of tolterodine or its pharmaceutically acceptable salts, prodrugs and metabolites thereof dispersed in a rate controlling polymeric matrix comprising (1) a pH independent gelling polymer, such as polyethylene oxide, (2) pH dependent gelling polymer, such as sodium CM-cellulose (3) a film coating polymer component, such as Eudragit RS100 and other conventional tablet functional excipients. The formulation such as tablets or minitablets in capsules of the present invention relates to a 24 h controlled release dosage form useful for the treatment of urge incontinence and other symptoms of unstable or overactive urinary bladder. The invention also relates to a process for the preparation of controlled release mucoadhesive matrix formulation containing tolterodine in a tablet or mini tablets in capsule dosage form. For example, controlled-release mucoadhesive matrix tablets were prepared by wet granulation of tolterodine tartrate 2.0, polyethylene oxide-18 NF 7.0, sodium CM-cellulose 3.0, lactose anhydrous 20.0, microcryst. cellulose 51.8, polyvinylpyrrolidone K-30 5.0, Eudragit RS 100 10.0, iso-Pr alc. 72, and acetone 48, granules obtained were dried, lubricated with colloidal silica 0.1, talc 0.1, and magnesium stearate 1.0 mg, resp., and compressed into core tablets. Eudragit L 100-55 3.0 was added to a mixture of iso-Pr alc. 25.6 and acetone 37.8, followed by tri-Et citrate 0.5 mg, resp., and the solution obtained was used as a barrier coating for core tablets.

IT Polysaccharides, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(acidic; preparation of controlled-release polymeric mucoadhesive matrix containing tolterodine for tablets or minitablets)

IT Drug delivery systems
(bioadhesive, mucoadhesive; preparation of controlled-release polymeric mucoadhesive matrix containing tolterodine for tablets or minitablets)

IT Drug delivery systems

(capsules, controlled-release, minitablets-containing; preparation of controlled-release polymeric mucoadhesive matrix containing tolterodine for tablets or minitablets)

IT Alcohols, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(fatty; preparation of controlled-release polymeric mucoadhesive matrix containing tolterodine for tablets or minitablets)

IT Cereal (grain)
(hydrolyzed, solids; preparation of controlled-release polymeric mucoadhesive matrix containing tolterodine for tablets or minitablets)

IT Bladder, disease
(incontinence, treatment of; preparation of controlled-release polymeric mucoadhesive matrix containing tolterodine for tablets or minitablets)

IT Polyesters, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(lactic acid-based; preparation of controlled-release polymeric mucoadhesive matrix containing tolterodine for tablets or minitablets)

IT Polymers, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(matrix; preparation of controlled-release polymeric mucoadhesive matrix containing tolterodine for tablets or minitablets)

IT Drug delivery systems
(oral, controlled-release; preparation of controlled-release polymeric mucoadhesive matrix containing tolterodine for tablets or minitablets)

IT Bladder, disease
(overactive bladder, treatment of; preparation of controlled-release polymeric mucoadhesive matrix containing tolterodine for tablets or minitablets)

IT Coating materials
(polymer film; preparation of controlled-release polymeric mucoadhesive matrix containing tolterodine for tablets or minitablets)

IT Dissolution
Gelation agents
Gums and Mucilages
Plasticizers
(preparation of controlled-release polymeric mucoadhesive matrix containing tolterodine for tablets or minitablets)

IT Adhesins
Agglutinins and Lectins
Bentonite, biological studies
Biopolymers
Carbohydrates, biological studies
Clays, biological studies
Gelatins, biological studies
Glycoproteins
Hydrocarbon oils
Kaolin, biological studies
Polyesters, biological studies
Polyoxyalkylenes, biological studies
Smectite-group minerals
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation of controlled-release polymeric mucoadhesive matrix containing tolterodine for tablets or minitablets)

IT Drug delivery systems

(tablets, controlled-release; preparation of controlled-release polymeric mucoadhesive matrix containing tolterodine for tablets or minitablets)

IT Fats and Glyceridic oils, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(vegetable, hydrogenated; preparation of controlled-release polymeric mucoadhesive matrix containing tolterodine for tablets or minitablets)

IT Granulation
(wet; preparation of controlled-release polymeric mucoadhesive matrix containing tolterodine for tablets or minitablets)

IT 9003-01-4D, crosslinked
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Carbopol; preparation of controlled-release polymeric mucoadhesive matrix containing tolterodine for tablets or minitablets)

IT 9003-39-8D, crosslinked
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Crospovidone; preparation of controlled-release polymeric mucoadhesive matrix containing tolterodine for tablets or minitablets)

IT 9010-88-2, Eudragit NE 30D
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Eudragit NE 50D; preparation of controlled-release polymeric mucoadhesive matrix containing tolterodine for tablets or minitablets)

IT 9050-36-6, Maltodextrin
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Mor-Rex; preparation of controlled-release polymeric mucoadhesive matrix containing tolterodine for tablets or minitablets)

IT 7631-86-9, Silica, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(colloidal; preparation of controlled-release polymeric mucoadhesive matrix containing tolterodine for tablets or minitablets)

IT 9004-34-6, Cellulose, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(microcryst.; preparation of controlled-release polymeric mucoadhesive matrix containing tolterodine for tablets or minitablets)

IT 124937-51-5, Tolterodine 124937-52-6, Tolterodine tartrate
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation of controlled-release polymeric mucoadhesive matrix containing tolterodine for tablets or minitablets)

IT 50-70-4, Sorbitol, biological studies 50-99-7, D-Glucose, biological studies 56-40-6, Glycine, biological studies 57-11-4, Stearic acid, biological studies 57-48-7, Fructose, biological studies 57-50-1, Sucrose, biological studies 69-65-8, D-Mannitol 77-89-4, Acetyl triethyl citrate 77-90-7, Acetyl tributyl citrate 79-41-4D, Methacrylic acid, derivs., polymers 84-66-2, Diethyl phthalate 84-74-2, Dibutyl phthalate 87-89-8, Inositol 88-99-3, Phthalic acid, biological studies 102-76-1, Triacetin 108-32-7, Propylene carbonate 109-43-3, Dibutyl sebacate 112-92-5, Stearyl alcohol 117-81-7, Dioctyl phthalate 134-03-2, Sodium ascorbate 471-34-1, Calcium carbonate, biological studies 557-04-0, Magnesium stearate 557-05-1, Zinc stearate 585-86-4, Lactitol 1327-43-1, Magnesium aluminum silicate 1344-95-2, Calcium silicate 1592-23-0, Calcium stearate 4070-80-8, Sodium stearyl fumarate 7789-77-7, Dibasic calcium phosphate dihydrate 9000-01-5, Acacia gum 9000-07-1, Carrageenan 9000-11-7, Carboxymethyl cellulose 9000-30-0, Guar gum 9000-36-6, Karaya gum 9000-40-2,

Locust bean gum 9000-65-1, Tragacanth gum 9000-69-5, Pectin 9002-18-0, Agar 9002-88-4D, Polyethylene, alkyl ethers 9003-01-4, Poly(acrylic acid) 9003-39-8, Polyvinylpyrrolidone 9004-32-4, Sodium CM-cellulose 9004-38-0, CAP 9004-53-9, Dextrin 9004-57-3, Ethyl cellulose 9004-61-9, Hyaluronic acid 9004-62-0, Hydroxyethyl cellulose 9004-64-2, Hydroxypropyl cellulose 9004-65-3, Hypromellose 9004-67-5, Methyl cellulose 9005-25-8, Starch, biological studies 9005-32-7, Alginic acid 9005-38-3, Sodium alginate 9005-65-6, Polysorbate 80 9005-82-7, Amylose 9012-76-4, Chitosan 9050-31-1, HPMCP 9063-38-1, Sodium starch glycolate 10101-41-4, Calcium sulfate dihydrate 12705-30-5, Celutab 13463-67-7, Titanium dioxide, biological studies 14807-96-6, Talc, biological studies 18662-40-3, Calcium sulfate monohydrate 25086-15-1, Eudragit S 100 25212-88-8, Eudragit L 100-55 25322-68-3, Polyethylene oxide 25496-72-4, Glyceryl monooleate 26009-03-0, Poly(glycolic acid) 26023-30-3, Poly[oxy(1-methyl-2-oxo-1,2-ethanediyl)] 26100-51-6, Poly(DL-lactic acid) 26124-68-5, Poly(glycolic acid) 26936-24-3, Eudragit FS 30D 31566-31-1, Glyceryl monostearate 33434-24-1, Eudragit RS 100 36653-82-4, Cetyl alcohol 39301-46-7, Calcium pectinate 53237-50-6 66828-18-0, Dextrate 71138-97-1, HPMCAS 74811-65-7, Croscarmellose sodium 77538-19-3, Glyceryl behenate 77938-63-7, Dextrose monohydrate 139061-06-6, Calcium lactate trihydrate 147335-38-4, Eudragit NE 40D 178806-61-6, Eudragit RLPO 476312-12-6, Carbopol 71G 869094-48-4, Maltrons
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation of controlled-release polymeric mucoadhesive matrix containing tolterodine for tablets or minitablets)

L1 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:1885 CAPLUS
DOCUMENT NUMBER: 142:79974
TITLE: Soft tablet containing high molecular weight cellulosics
INVENTOR(S): Wynn, David; Parikh, Nick
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 8 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004265373	A1	20041230	US 2003-608681	20030627
CA 2472432	AA	20041227	CA 2004-2472432	20040625
EP 1498114	A1	20050119	EP 2004-253844	20040625
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				

PRIORITY APPLN. INFO.: US 2003-607766 A 20030627
US 2003-608681 A 20030627

TI Soft tablet containing high molecular weight cellulosics
AB The invention relates to an immediate-release tablet capable of being chewed or disintegrated in the oral cavity, which comprises an active ingredient having an optional taste masking coating, and a matrix comprising hydroxyalkyl cellulose having a weight average mol. weight of 60,000-

5,000,000. The tablet has exceptionally good mouth-feel and stability. Thus, a coating solution contained cellulose acetate 43, Hypromellose phthalate 53, and Polysorbate-80 4%. Ibuprofen granules were obtained in the conventional manner and were then coated with the above taste-masking solution

ST soft tablet mol wt cellulose

IT Granulation
(dry granulation; soft tablet containing high mol. weight celluloses)

IT Drug delivery systems
(granules; soft tablet containing high mol. weight celluloses)

IT Bitterness
Coating materials
Compression
Molecular weight distribution
Viscosity
(soft tablet containing high mol. weight celluloses)

IT Carbohydrates, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(soft tablet containing high mol. weight celluloses)

IT Drug delivery systems
(tablets, immediate release; soft tablet containing high mol. weight celluloses)

IT Drug delivery systems
(tablets; soft tablet containing high mol. weight celluloses)

IT 9004-34-6, Cellulose, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(microcryst.; soft tablet containing high mol. weight celluloses)

IT 50-70-4, Sorbitol, biological studies 50-78-2, Acetylsalicylic acid 58-73-1, Diphenhydramine 69-65-8, Mannitol 87-99-0, Xylitol 90-82-4, Pseudoephedrine 103-90-2, Acetaminophen 125-71-3, Dextromethorphan 132-22-9, Chlorpheniramine 303-53-7, Cyclobenzaprine 5104-49-4, Flurbiprofen 9004-34-6D, Cellulose, ethers 9004-35-7 9004-62-0, Hydroxyethyl cellulose 9004-64-2, Hydroxypropyl cellulose 9004-65-3, Hydroxypropyl methyl cellulose 9032-42-2, Hydroxyethyl methyl cellulose 9050-31-1, Hypromellose phthalate 14838-15-4, Phenylpropanolamine 15307-86-5, Diclofenac 15687-27-1, Ibuprofen 22071-15-4, Ketoprofen 22204-53-1, Naproxen 37353-59-6, Hydroxymethyl cellulose 50679-08-8, Terfenadine 68844-77-9, Astemizole 71125-38-7, Meloxicam 77938-63-7, Dextrose monohydrate 79794-75-5, Loratadine 83799-24-0, Fexofenadine 83881-51-0, Cetirizine 162011-90-7, Rofecoxib 169590-42-5, Celecoxib
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(soft tablet containing high mol. weight celluloses)

L1 ANSWER 3 OF 23 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:993 CAPLUS
DOCUMENT NUMBER: 142:79963
TITLE: Soft tablets containing high molecular weight celluloses
INVENTOR(S): Wynn, David; Parikh, Nick
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 9 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English

09752899

FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004265372	A1	20041230	US 2003-607766	20030627
CA 2472432	AA	20041227	CA 2004-2472432	20040625
EP 1491184	A1	20041229	EP 2004-253843	20040625

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR

PRIORITY APPLN. INFO.: US 2003-607766 A 20030627
US 2003-608681 A 20030627

TI Soft tablets containing high molecular weight celluloses

AB An immediate release tablet capable of being chewed or subjected to disintegration in the oral cavity, comprises an active ingredient having an optional taste-masking coating, and a matrix comprising hydroxyalkyl cellulose having a weight average mol. weight of 60,000-5,000,000. The tablet has exceptionally good mouth-feel and stability. A coating solution was prepared by dispersing cellulose acetate 43, Hypromellose phthalate 53, and Polysorbate-80 4% in a solvent consisting of 90% acetone and 10% water under ambient conditions, so that the finished solution contained 10% of the coating materials. Ibuprofen granules prepared in the conventional way were then coated with the above taste-masking solution High weight average mol. weight hydroxyalkyl cellulose-containing tablets had significantly less of a grittiness feel in the mouth in comparison to those tablets lacking the high weight average mol. weight hydroxyalkyl cellulose.

ST soft tablet mol wt cellulose

IT Granulation
(dry granulation; soft tablets containing high mol. weight celluloses)

IT Bitterness
Coating materials
Compression
Dissolution
Molecular weight distribution
Solubilizers
(soft tablets containing high mol. weight celluloses)

IT Carbohydrates, biological studies
Polymers, biological studies
Polyoxyalkylenes, biological studies
Shellac
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(soft tablets containing high mol. weight celluloses)

IT Drug delivery systems
(tablets, enteric-coated; soft tablets containing high mol. weight celluloses)

IT Drug delivery systems
(tablets, immediate release; soft tablets containing high mol. weight celluloses)

IT 50-70-4, Sorbitol, biological studies 50-78-2, Acetylsalicylic acid 58-73-1, Diphenhydramine 69-65-8, Mannitol 79-41-4D, Methacrylic acid, esters, polymers 87-99-0, Xylitol 90-82-4, Pseudoephedrine 103-90-2, Acetaminophen 125-71-3, Dextromethorphan 132-22-9, Chlorpheniramine 303-53-7, Cyclobenzaprine 5104-49-4, Flurbiprofen 9002-89-5, Poly(vinyl alcohol) 9003-39-8, Polyvinylpyrrolidone 9004-32-4

9004-34-6D, Cellulose, ethers 9004-35-7 9004-36-8, Cellulose acetate butyrate 9004-38-0, Cellulose acetate phthalate 9004-57-3, Ethyl cellulose 9004-62-0, Hydroxyethyl cellulose 9004-64-2, Hydroxypropyl cellulose 9004-65-3, Hydroxypropyl methyl cellulose 9004-67-5, Methyl cellulose 9010-88-2, Ethyl acrylate-methyl methacrylate copolymer 9012-09-3, Cellulose triacetate 9032-42-2, Hydroxyethyl methyl cellulose 9050-31-1, Hydroxypropyl methyl cellulose phthalate 14838-15-4, Phenylpropanolamine 15307-86-5, Diclofenac 15687-27-1, Ibuprofen 22071-15-4, Ketoprofen 22204-53-1, Naproxen 25322-68-3, Polyethylene glycol 37353-59-6, Hydroxymethyl cellulose 50679-08-8, Terfenadine 53237-50-6, Polyvinyl acetate phthalate 68844-77-9, Astemizole 70535-77-2, Hydroxypropyl methyl cellulose acetate succinate 71125-38-7, Meloxicam 77938-63-7, Dextrose monohydrate 79794-75-5, Loratadine 83799-24-0, Fexofenadine 83881-51-0, Cetirizine 162011-90-7, Rofecoxib 169590-42-5, Celecoxib
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(soft tablets containing high mol. weight celluloses)

L1 ANSWER 4 OF 23 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:368929 CAPLUS
DOCUMENT NUMBER: 140:363062
TITLE: Pharmaceutical compositions of ganciclovir
INVENTOR(S): Mathur, Rajeev Shankar; Kumar, Pananchukunnath Manoj; Roy, Sunilendu Bhushan; Malik, Rajiv
PATENT ASSIGNEE(S): Ranbaxy Laboratories Limited, India
SOURCE: PCT Int. Appl., 21 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004037263	A1	20040506	WO 2003-IB4664	20031022
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003274410	A1	20040513	AU 2003-274410	20031022
EP 1556050	A1	20050727	EP 2003-758391	20031022
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
US 2006189565	A1	20060824	US 2006-532024	20060407
PRIORITY APPLN. INFO.:			IN 2002-DE1058 A	20021022
			WO 2003-IB4664 W	20031022

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

IT Drug delivery systems
(tablets; stable pharmaceutical compns. of ganciclovir)
IT 50-70-4, Sorbitol, biological studies 50-99-7, Glucose, biological

studies 57-50-1, Sucrose, biological studies 63-42-3, Lactose 69-65-8, D-Mannitol 7789-77-7, Dibasic calcium phosphate dihydrate 9000-01-5, Acacia gum 9000-30-0, Guar gum 9000-65-1, Traganth gum 9003-39-8, PVP 9004-32-4, Sodium CMC 9004-64-2, Hydroxypropyl cellulose 9004-65-3, Hydroxypropyl methyl cellulose 9004-67-5, Methyl cellulose 9005-25-8, Starch, biological studies 9005-32-7, Alginic acid 9063-38-1, Sodium starch glycolate 10031-30-8 10101-41-4, Calcium sulfate dihydrate 25322-68-3, Polyethylene glycol 74811-65-7, Croscarmellose sodium 77938-63-7, Dextrose monohydrate 82410-32-0, Ganciclovir 139061-06-6
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(stable pharmaceutical compns. of ganciclovir)

L1 ANSWER 5 OF 23 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:145843 CAPLUS
DOCUMENT NUMBER: 141:355096
TITLE: Powdered and granular materials used in the fabrication of compressed tablets
AUTHOR(S): Delattre, Luc
CORPORATE SOURCE: Laboratoire de Technologie Pharmaceutique, Departement de Pharmacie, Faculte de Medecine, Universite de Liege, Liege, Belg.
SOURCE: Bulletin de la Societe Royale des Sciences de Liege (2003), 72(5), 317-339
CODEN: BSRSA6; ISSN: 0037-9565
PUBLISHER: Societe Royale des Sciences de Liege
DOCUMENT TYPE: Journal
LANGUAGE: French
REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT
TI Powdered and granular materials used in the fabrication of compressed tablets
AB The effect of Mg stearate mixing time on the crushing strength of tablets was determined
ST compressed tablet property
IT Drug delivery systems
(granules; powdered and granular materials in fabrication of compressed tablets)
IT Compaction
Compression
Crushing strength
Shear
(powdered and granular materials in fabrication of compressed tablets)
IT Drug delivery systems
(tablets; powdered and granular materials in fabrication of compressed tablets)
IT Granulation
(wet; powdered and granular materials in fabrication of compressed tablets)
IT 9004-34-6, Avicel PH102, biological studies
RL: PEP (Physical, engineering or chemical process); PYP (Physical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(microcryst.; powdered and granular materials in fabrication of compressed tablets)
IT 63-42-3, Tablettose 557-04-0 5965-66-2, Pharmatose DCL 21 7789-77-7,

Dibasic calcium phosphate dihydrate 12705-30-5, Celutab 64044-51-5, Lactose monohydrate 77938-63-7, Dextrose monohydrate
RL: PEP (Physical, engineering or chemical process); PYP (Physical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(powdered and granular materials in fabrication of compressed tablets)

L1 ANSWER 6 OF 23 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:737151 CAPLUS
DOCUMENT NUMBER: 139:250306
TITLE: Soft tablets containing high molecular weight polyethylene oxide
INVENTOR(S): Luber, Joseph; Bunick, Frank J.
PATENT ASSIGNEE(S): McNeil-PPC, Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 7 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003175336	A1	20030918	US 2002-97000	20020313
US 6753009	B2	20040622		
CA 2421685	AA	20030913	CA 2003-2421685	20030312
PRIORITY APPLN. INFO.:			US 2002-97000 A	20020313

REFERENCE COUNT: 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

TI Soft tablets containing high molecular weight polyethylene oxide
AB The invention relates to an immediate release tablet capable of being chewed or disintegrated in the oral cavity, which comprises a pharmaceutically active ingredient, and a matrix comprising polyethylene oxide having a weight average mol. weight of from about 500,000 to about 10,000,000.
The tablet possesses exceptionally good mouthfeel and stability. For example, tablets were formulated containing polyethylene oxide (average mol. weight 5,000,000), vitamin E granules 13.3, erythritol 100, crospovidone 25, colorant 2.5, coated ibuprofen 282.1, flavors 15, sucralose 10, dextrose monohydrate 658, and lubricants 7.5 parts.
ST immediate release soft tablet matrix PEG
IT Antacids
Antioxidants
(immediate-release matrixes containing high mol. weight PEG and antioxidants for soft tablets)
IT Polyoxyalkylenes, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(immediate-release matrixes containing high mol. weight PEG and antioxidants for soft tablets)
IT Drug delivery systems
(tablets, buccal; immediate-release matrixes containing high mol. weight PEG and antioxidants for soft tablets)
IT Drug delivery systems
(tablets, chewable; immediate-release matrixes containing high mol. weight PEG and antioxidants for soft tablets)

IT Drug delivery systems
(tablets, controlled-release; immediate-release matrixes containing high mol. weight PEG and antioxidants for soft tablets)
IT 50-78-2, Acetylsalicylic acid 58-73-1, Diphenhydramine 59-02-9, α-Tocopherol 90-82-4, Pseudoephedrine 103-90-2, Acetaminophen 113-92-8 121-79-9, Propyl gallate 125-71-3, Dextromethorphan 128-37-0, biological studies 303-53-7, Cyclobenzaprine 319-89-1, Tetrahydroxyquinone 603-50-9, Bisacodyl 915-30-0, Diphenoxylate 1406-18-4, Vitamin E 5104-49-4, Flurbiprofen 7397-62-8, Butyl hydroxyacetate 7440-69-9, Bismuth, biological studies 9031-11-2, Lactase 14838-15-4, Phenylpropanolamine 15307-86-5, Diclofenac 15687-27-1, Ibuprofen 22071-15-4, Ketoprofen 22204-53-1, Naproxen 25322-68-3, Polyethylene oxide 50679-08-8, Terfenadine 51481-61-9, Cimetidine 53179-11-6, Loperamide 66357-35-5, Ranitidine 68844-77-9, Astemizole 71125-38-7, Meloxicam 76824-35-6, Famotidine 79794-75-5, Loratadine 83799-24-0, Fexofenadine 83881-51-0, Cetirizine 162011-90-7, Rofecoxib 169590-42-5, Celecoxib 179474-81-8, Prucalopride
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(immediate-release matrixes containing high mol. weight PEG and antioxidants for soft tablets)

L1 ANSWER 7 OF 23 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:8105 CAPLUS
DOCUMENT NUMBER: 138:61356
TITLE: Method to aid smoking cessation using dextrose and/or levulose
INVENTOR(S): West, Robert; Hajek, Peter
PATENT ASSIGNEE(S): UK
SOURCE: Brit. UK Pat. Appl., 7 pp.
CODEN: BAXXDU
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 2376885	A1	20021231	GB 2001-15568	20010626
PRIORITY APPLN. INFO.:			GB 2001-15568	20010626

AB The present invention concerns methods of treating patients for nicotine and tobacco addiction, for alleviating nicotine withdrawal, for improving the effects of other smoking cessation therapies and as longterm smoking cessation maintenance therapy. The invention comprises pharmaceutical compns. comprising dextrose monohydrate and/or levulose in combination with amfebutamone or any other non-nicotine smoking cessation method whose efficacy can be enhanced by addition of dextrose or levulose. Specific combinations of drugs (dextrose and/or levulose combined with amfebutamone) as well as dextrose and/or levulose in combination with certain drug classes (e.g., stimulant drugs, antidepressants, and drugs used in treatment of psychoactive substance use disorders) are described. These compns. are also contemplated for use in the treatment of alcoholism, cocaine dependence and other drug dependencies.
IT Drug delivery systems
(tablets, chewable; compns. containing dextrose and/or levulose in combination with amfebutamone for smoking cessation and treatment of

alcoholism and drug dependence)

L1 ANSWER 8 OF 23 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2002:674574 CAPLUS
DOCUMENT NUMBER: 137:206555
TITLE: Soft tablet containing dextrose monohydrate
INVENTOR(S): Bunick, Frank J.; Luber, Joseph
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 5 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002122823	A1	20020905	US 2000-752899	20001229
PRIORITY APPLN. INFO.:			US 2000-752899	20001229

TI Soft tablet containing dextrose monohydrate
AB A tablet capable of being chewed or disintegrated in the oral cavity, comprises an active ingredient, and a matrix containing directly compressible dextrose monohydrate and sucralose, the tablet being substantially fat free and the matrix being substantially free of non-saccharide water-soluble polymeric binders. Thus, tablets contained sucralose 8.0 FD&C Yellow #6 Al Lake 3.0, orange flavor 10.0 Crospovidone 15.0, coated ibuprofen 140.6, dextrose monohydrate 850.0, and Mg stearate 7.5 mg/tablet.
ST soft tablet dextrose monohydrate
IT Antioxidants
Compression
Dyes
Flavoring materials
Granulation
Human
Lubricants
Particle size distribution
Preservatives
Surfactants
Sweetening agents
(soft tablets containing dextrose monohydrate
)
IT Drug delivery systems
(tablets; soft tablets containing dextrose monohydrate)
IT 9003-39-8, Polyvinylpyrrolidone 9004-32-4, Carboxymethyl cellulose
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(crosslinked; soft tablets containing dextrose monohydrate)
IT 9004-34-6, Cellulose, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(microcryst.; soft tablets containing dextrose monohydrate)
IT 57-11-4, Stearic acid, biological studies 58-73-1, Diphenhydramine 90-82-4, Pseudoephedrine 103-90-2, Acetaminophen 113-92-8, Chlorpheniramine 125-71-3, Dextromethorphan 471-34-1, Calcium

carbonate, biological studies 546-93-0, Magnesium carbonate 557-04-0, Magnesium stearate 1309-42-8, Magnesium hydroxide 1309-48-4, Magnesium oxide, biological studies 2783-94-0, FD&C Yellow #6 9005-25-8, Starch, biological studies 9063-38-1, Sodium starch glycolate 14431-43-7, Dextrose monohydrate 15687-27-1, Ibuprofen 21645-51-2, Aluminum hydroxide, biological studies 56038-13-2, Sucralose
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(soft tablets containing dextrose monohydrate
)

L1 ANSWER 9 OF 23 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2002:674573 CAPLUS
DOCUMENT NUMBER: 137:206554
TITLE: Chewable tablets containing hydrate excipients.
INVENTOR(S): Bunick, Frank J.; Luber, Joseph
PATENT ASSIGNEE(S): McNeil-PPC, Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 5 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002122822	A1	20020905	US 2000-752601	20001229
US 6814978	B2	20041109		
US 2003175339	A1	20030918	US 2003-413804	20030415
PRIORITY APPLN. INFO.:			US 2000-752601	A1 20001229

REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

TI Chewable tablets containing hydrate excipients.
AB The invention relates to a process for preparing a soft tablet capable of being chewed or disintegrated in the oral cavity. The tablet is prepared by forming a tablet having a friability of less than about 2% from a mixture comprising a pharmaceutically active ingredient, an excipient in the form of a hydrate, and a water-swellable excipient, and then applying sufficient energy, preferably in the form of heat, to the tablet for a sufficient time to decrease the hardness of the tablet by at least about 20%. A composition contained sucralose 8.0, coated ibuprofen (69.0%) 140.6, flavor 10.0, dextrose monohydrate 850.0, Crospovidone 15.0, and Mg stearate 7.5.
ST tablet chewable hydrate excipient
IT Compression
Hardness (mechanical)
Particle size
(chewable tablets containing hydrate excipients)
IT Drug delivery systems
(tablets, chewable; chewable tablets containing hydrate excipients)
IT 9003-39-8D, crosslinked
RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Crospovidone; chewable tablets containing hydrate excipients)
IT 5949-29-1, Citric acid monohydrate 7782-85-6, Phosphoric acid, disodium

salt, heptahydrate 7789-77-7, Dibasic calcium phosphate dihydrate 9004-34-6, Cellulose, biological studies 9004-53-9, Dextrin 9005-25-8, Starch, biological studies 9005-32-7, Alginic acid 9050-36-6, Maltodextrin 9063-38-1, Sodium starch glycolate 10028-24-7, Phosphoric acid, disodium salt, dihydrate 10039-32-4, Phosphoric acid, disodium salt, dodecahydrate 10049-21-5, Monosodium phosphate monohydrate 13472-35-0, Monosodium phosphate dihydrate 14431-43-7, Dextrose monohydrate 64044-51-5, Lactose monohydrate 74811-65-7, Croscarmellose sodium
RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(chewable tablets containing hydrate excipients)

IT 58-73-1, Diphenhydramine 90-82-4, Pseudoephedrine 103-90-2, Acetaminophen 113-92-8, Chlorpheniramine 125-71-3, Dextromethorphan 471-34-1, Calcium carbonate, biological studies 546-93-0, Magnesium carbonate 1309-42-8, Magnesium hydroxide 1309-48-4, Magnesium oxide, biological studies 15687-27-1, Ibuprofen 21645-51-2, Aluminum hydroxide, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(chewable tablets containing hydrate excipients)

L1 ANSWER 10 OF 23 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2001:434870 CAPLUS
DOCUMENT NUMBER: 135:51047
TITLE: Nanoparticulate eplerenone compositions
INVENTOR(S): Thosar, Shilpa S.; Gokhale, Rajeev D.; Tolbert, Dwain S.; Desai, Subhash
PATENT ASSIGNEE(S): Pharmacia Corporation, USA
SOURCE: PCT Int. Appl., 64 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001041770	A2	20010614	WO 2000-US30179	20001204
WO 2001041770	A3	20011122		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 2001017562	A5	20010618	AU 2001-17562	20001204
EP 1175220	A2	20020130	EP 2000-980277	20001204
EP 1175220	B1	20050427		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
EP 1527782	A1	20050504	EP 2004-30120	20001204
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR				
AT 293977	E	20050515	AT 2000-980277	20001204

PT 1175220	T	20050729	PT 2000-980277		20001204
ES 2240209	T3	20051016	ES 2000-980277		20001204
US 2002006919	A1	20020117	US 2000-732246		20001207
US 2003212053	A1	20031113	US 2003-417602		20030416
PRIORITY APPLN. INFO.:			US 1999-169658P	P	19991208
			US 2000-208981P	P	20000602
			EP 2000-980277	A3	20001204
			WO 2000-US30179	W	20001204
			US 2000-732246	A3	20001207

AB There is provided a pharmaceutical composition comprising eplerenone in solid particulate form, wherein at least 90 of the eplerenone particles are smaller than about 15 μm, for example about 0.01 to about 1 μm, in diameter The composition can be adapted for oral administration, for example as a tablet or capsule comprising eplerenone in a unit dosage amount of about 10 to about 1000 mg and one or more excipients. An immediate release tablet was prepared containing nanoparticulate eplerenone 25.00, lactose monohydrate 35.70, microcryst. cellulose 15.38, croscarmellose sodium 4.25, HPMC 2.55, Na lauryl sulfate 0.85, Mg stearate 0.42, and Opadry White YS-1-18027A 2.55 mg/tablet.

ST eplerenone nanoparticle tablet capsule

IT Drug delivery systems
(tablets; nanoparticulate eplerenone compns.)

IT 50-70-4, Sorbitol, biological studies 50-99-7, Dextrose, biological studies 56-40-6, Glycine, biological studies 57-11-4, Stearic acid, biological studies 57-50-1, Sucrose, biological studies 63-42-3, Lactose 69-65-8, D-Mannitol 87-89-8, Inositol 87-99-0, Xylitol 112-80-1, Oleic acid, biological studies 121-54-0, Benzethonium chloride 123-03-5, Cetylpyridinium chloride 127-09-3, Sodium acetate 143-19-1, Sodium oleate 151-21-3, Sodium lauryl sulfate, biological studies 328-39-2, Leucine 471-34-1, Calcium carbonate, biological studies 532-32-1, Sodium benzoate 557-04-0, Magnesium stearate 577-11-7, Dioctyl sodium sulfosuccinate 822-16-2, Sodium stearate 1327-43-1, Magnesium aluminum silicate 1338-39-2, Sorbitan monolaurate 1338-41-6, Sorbitan monostearate 1338-43-8, Sorbitan monooleate 1592-23-0, Calcium stearate 2717-15-9, Triethanolamine oleate 3097-08-3, Magnesium lauryl sulfate 7631-86-9, Silica, biological studies 7647-14-5, Sodium chloride, biological studies 7704-73-6, Sodium fumarate 7789-77-7, Dicalcium phosphate dihydrate 9000-30-0, Guar gum 9000-36-6, Karaya gum 9000-40-2, Locust bean gum 9000-65-1, Gum tragacanth 9000-69-5, Pectin 9002-18-0, Agar 9003-39-8, Pvp 9004-32-4 9004-32-4, CM-cellulose 9004-34-6, Cellulose, biological studies 9004-57-3, Ethyl cellulose 9004-64-2, Hydroxypropyl cellulose 9004-65-3, HPMC 9004-67-5, Methyl cellulose 9004-99-3, Polyoxyethylene stearate 9005-25-8, Starch, biological studies 9005-32-7, Alginic acid 9005-64-5, Polysorbate 20 9005-65-6, Polysorbate 80 9005-82-7, Amylose 9036-19-5, Octoxynol 9 9063-38-1, Sodium starch glycolate 10043-35-3, Boric acid, biological studies 10101-41-4, Calcium sulfate dihydrate 14431-43-7, Dextrose monohydrate 14807-96-6, Talc, biological studies 18641-57-1, Glyceryl behenate 18662-40-3, Sulfuric acid, calcium salt (1:1), monohydrate 25301-02-4, Tyloxapol 25322-68-3, Peg 26027-38-3, Nonoxynol 9 26266-57-9, Sorbitan monopalmitate 27306-76-9, Polyoxyethylene cetylstearyl ether 31566-31-1, Glyceryl monostearate 37321-62-3, Propylene glycol laurate 64044-51-5, Lactose monohydrate 66828-18-0, Dextrate 74811-65-7, Croscarmellose sodium 106392-12-5, Poloxamer 139061-06-6, Propanoic acid, 2-hydroxy-, calcium salt (2:1), trihydrate

RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(nanoparticulate eplerenone compns.)

L1 ANSWER 11 OF 23 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2001:136959 CAPLUS
DOCUMENT NUMBER: 134:183494
TITLE: Orally dissolvable prenatal multi-vitamin
INVENTOR(S): Devries, Tina; Valentine, William; Valentine, William K.
PATENT ASSIGNEE(S): Warner Chilcott Laboratories Ireland Limited, USA
SOURCE: PCT Int. Appl., 38 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2001011991	A1	20010222	WO 2000-US40557		20000803
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG					
US 6495177	B1	20021217	US 2000-539850		20000331
PRIORITY APPLN. INFO.:			US 1999-148803P	P	19990813
			US 1999-148806P	P	19990813
			US 2000-539850	A	20000331

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

AB The present invention provides an orally administrable nutritional supplement which is highly palatable, such as a chewable prenatal vitamin/mineral supplement. The supplement is preferably made in the form of a tablet that, upon chewing, dissolves rapidly in the mouth. The tablet is particularly suitable for administration of vitamins and minerals to women during pregnancy. The invention also includes methods of making and using such supplements.

ST vitamin mineral supplement tablet

IT Drug delivery systems
(tablets, chewable; orally dissolvable prenatal multi-vitamin)

IT 50-70-4, Sorbitol, biological studies 50-81-7, Vitamin C, biological studies 50-99-7, Dextrose, biological studies 57-48-7, D-Fructose, biological studies 57-50-1, Sucrose, biological studies 58-86-6, D-Xylose, biological studies 58-95-7, Vitamin E acetate 59-30-3, Folic acid, biological studies 59-30-3D, Folic acid, salts 59-43-8, Vitamin B1, biological studies 59-67-6, Niacin, biological studies 63-42-3, Lactose 67-97-0, Vitamin D3 68-19-9, Vitamin B12 69-65-8, Mannitol 69-79-4, Maltose 83-88-5, Vitamin B2, biological studies 98-92-0, Niacinamide 134-03-2, Sodium ascorbate 141-01-5, Ferrous fumarate 557-04-0, Magnesium stearate 1406-18-4, Vitamin E 7235-40-7,

β-Carotene 7439-89-6, Iron, biological studies 7439-89-6D, Iron, compds., biological studies 7440-70-2, Calcium, biological studies 7758-87-4, Tricalcium phosphate 8059-24-3, Vitamin B6 9003-39-8, Polyvinyl pyrrolidone 9004-34-6, Cellulose, biological studies 9016-00-6, Dimethyl polysiloxane 9050-36-6, Maltodextrin 11103-57-4, Provitamin A 14431-43-7, Dextrose monohydrate
RL: FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(orally dissolvable prenatal multi-vitamin)

L1 ANSWER 12 OF 23 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1997:471006 CAPLUS
DOCUMENT NUMBER: 127:152888
TITLE: Potassium carbonate as a desiccant in effervescent tablets
AUTHOR(S): Wells, Mickey L.; Wood, Daniel L.; Sanftleben, Ronald; Shaw, Kelley; Hottovy, Jeff; Weber, Thomas; Geoffroy, Jean-Marie; Alkire, Todd G.; Emptage, Michael R.; Sarabia, Rafael
CORPORATE SOURCE: Glaxo Wellcome Inc., Research Triangle Park, NC, 27709, USA
SOURCE: International Journal of Pharmaceutics (1997), 152(2), 227-235
CODEN: IJPHDE; ISSN: 0378-5173
PUBLISHER: Elsevier
DOCUMENT TYPE: Journal
LANGUAGE: English
TI Potassium carbonate as a desiccant in effervescent tablets
AB A central composite study design was used to determine the moisture scavenging effect of 0-2% weight/weight potassium carbonate in an effervescent dosage form containing 0.2-1.3% weight/weight total moisture. Total moisture content of the tablets was calculated by adding the water contribution of each ingredient based on loss on drying or Karl Fischer data. Tablets were directly compressed on a rotary tablet press, packaged in cold form foil/foil blisters, and then thermally stressed by exposure to 75°C for 3 h. In this study, exposure of effervescence in such a manner has been shown to release water of hydration from dextrose monohydrate, thus giving a convenient means of adding water and then 'activating' it to perform rapid moisture stability studies. After thermal stressing, tablets were given a rating from 0-7 (least to most) as to the degree of tablet mottling due to effervescent base degradation Response surface regression of the data resulted in a quadratic equation with an adjusted R2 of 0.92 and no evidence of lack of fit (P = 0.85). Anal. of the data showed the optimal level of potassium carbonate to be 1.3% weight/weight for the formulations tested. This level of potassium carbonate will accommodate total moisture levels up to 0.4% weight/weight and still prevent effervescent base degradation
ST potassium carbonate desiccant effervescent pharmaceutical tablet
IT Particle size
(potassium carbonate as desiccant in effervescent tablets)
IT Drying agents
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(potassium carbonate as desiccant in effervescent tablets)
IT Drug delivery systems
Drug delivery systems
(tablets, effervescent; potassium carbonate as desiccant in

effervescent tablets)
IT 584-08-7, Potassium carbonate
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(potassium carbonate as desiccant in effervescent tablets)

L1 ANSWER 13 OF 23 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1997:204347 CAPLUS
DOCUMENT NUMBER: 126:255506
TITLE: Compressed tablet transitory lubricant system
INVENTOR(S): Valentine, William; Valentine, William K.
PATENT ASSIGNEE(S): Advanced Technology Pharmaceuticals Corporation, USA
SOURCE: U.S., 6 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5609883	A	19970311	US 1994-307922	19940916
PRIORITY APPLN. INFO.:			US 1994-307922	19940916

TI Compressed tablet transitory lubricant system
AB A method is provided for making fast dissolving storage stable tablets by compression on standard high speed tablet production machinery wherein the formulation contains a carbohydrate having a special particle size and/or structure, in combination with controlled amts. of a transitory liquid as a lubricant, which liquid is removed following compression. Dextrose monohydrate/maltodextrin coagglomerate 845.6, 33.3% coated chlorpheniramine maleate 3.4, 33.3% coated pseudoephedrine.HCl 50.0, 10% dextromethorphan.HBr magnesium trisilicate 56.0, spray dried lemon flavor 45.0 g, and Et alc. 44 mL were blended then ethanol was added and mixed until a uniformly damp granulation was formed. The damp granulation was pressed on a tablet press and dried at 37° for 30 min. The finished tablets increased in hardness to 5-6 Kp and demonstrated enhanced liquescent characteristics.
ST compressed pharmaceutical tablet carbohydrate ethanol
IT Lubricants
Particle size
(fast dissolving compressed tablet with enhanced liquescent character)
IT Alcohols, uses
RL: NUU (Other use, unclassified); USES (Uses)
(fast dissolving compressed tablet with enhanced liquescent character)
IT Carbohydrates, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(fast dissolving compressed tablet with enhanced liquescent character)
IT Drug delivery systems
(tablets, compressed; fast dissolving compressed tablet with enhanced liquescent character)
IT 64-17-5, Ethanol, uses
RL: NUU (Other use, unclassified); USES (Uses)
(fast dissolving compressed tablet with enhanced liquescent

character)
IT 50-99-7, Dextrose, biological studies 113-92-8, Chlorpheniramine maleate 125-69-9, Dextromethorphan hydrobromide 345-78-8, Pseudoephedrine hydrochloride 9050-36-6, Maltodextrin 14431-43-7, Dextrose monohydrate
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(fast dissolving compressed tablet with enhanced liquescent character)

L1 ANSWER 14 OF 23 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1996:155953 CAPLUS
DOCUMENT NUMBER: 124:270037
TITLE: Using starch in tabletting
AUTHOR(S): Vanhemelrijk, J.; Heume, M.
CORPORATE SOURCE: Cerestar Euro Centre Food, Vilvoorde, 1800, Belg.
SOURCE: Agro-Food-Industry Hi-Tech (1995), 6(5), 9-10
CODEN: AIHTEI; ISSN: 1120-6012
PUBLISHER: TeknoScienze srl
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English
AB A review with no refs. Starch, in its many basic and chemical or phys. modified forms has been used for many years in tablet production Its hydrolysis products, maltodextrin, glucose syrup solids and dextrose monohydrate all find specialist performance niches. In addition, dextrose when fully hydrogenated to sorbitol offers a newer tabletting agent with specialist potential. Work being carried out on tabletting with starch and derivs. is described.
ST review starch tablet
IT Pharmaceutical dosage forms
(tablets, starch in tabletting)

L1 ANSWER 15 OF 23 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1995:694438 CAPLUS
DOCUMENT NUMBER: 123:93108
TITLE: Effect of different excipients on release characteristics of acetylsalicylic acid from compressed pellets
AUTHOR(S): Torrado-Santiago; Torrado, J. J.; Cadorniga, R.
CORPORATE SOURCE: Fac. Pharm., Complutense Univ., Madrid, Spain
SOURCE: Pharmazie (1995), 50(7), 476-8
CODEN: PHARAT; ISSN: 0031-7144
PUBLISHER: Govi-Verlag Pharmazeutischer Verlag
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The release of acetylsalicylic acid matrix tablets prepared from pellets was studied with different hydrophilic excipients [microcryst. cellulose (Avicel PH 101), wheat starch and dextrose monohydrate] in different proportions. The release process was zero-order or first-order. The dissoln. efficiency varied between 23 and 75% in 8 h. MCC is the excipient with a higher compression protecting effect on the pellets during tablet compaction. In vitro drug release depends on the MCC content of the tablets.

L1 ANSWER 16 OF 23 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1993:678520 CAPLUS
DOCUMENT NUMBER: 119:278520
TITLE: "In vitro" drug release of AAS matrix tablets

09752899

AUTHOR(S): Torrado, S.; Torrado, Susana; Torrado V., J.; Cadorniga, R.
CORPORATE SOURCE: Univ. Complutense, Madrid, 28040, Spain
SOURCE: Proc. Int. Symp. Controlled Release Bioact. Mater., 20th (1993), 370-1. Editor(s): Roseman, Theodore J.; Peppas, Nicholas A.; Gabelnick, Henry L. Controlled Release Soc.: Deerfield, Ill.
CODEN: 59LOAL
DOCUMENT TYPE: Conference
LANGUAGE: English
TI "In vitro" drug release of AAS matrix tablets
AB Matrix tablets of acetylsalicylic acid (AAS) were produced by compression of AAS coated pellet with acrylic resins (Eudragit RS). The drug release profile of the AAS pellets after compression with different excipients (microcryst. cellulose, starch and dextrose monohydrate) was studied.
ST acetylsalicylate release matrix tablet
IT Solution rate
(of acetylsalicylic acid, from matrix tablets)
IT Pharmaceutical dosage forms
(tablets, matrix, acetylsalicylic acid release from)
IT 50-78-2, Acetylsalicylic acid
RL: PROC (Process)
(release of, from matrix tablets)

L1 ANSWER 17 OF 23 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1988:479708 CAPLUS
DOCUMENT NUMBER: 109:79708
TITLE: Sustained-release pharmaceutical containing fatty acid sugar esters as excipients
INVENTOR(S): Jansen, Frans Herwigjan; Hendrickx, Jean
PATENT ASSIGNEE(S): Sanico, N. V., Belg.; N. V. Gantax S. A.
SOURCE: Eur. Pat. Appl., 13 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 230332	A1	19870729	EP 1987-200031	19870112
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
NL 8600050	A	19870803	NL 1986-50	19860113
FI 8700092	A	19870714	FI 1987-92	19870112
NO 8700104	A	19870714	NO 1987-104	19870112
DK 8700161	A	19870714	DK 1987-161	19870113
ZA 8700216	A	19870826	ZA 1987-216	19870113
JP 62209025	A2	19870914	JP 1987-7403	19870113
PRIORITY APPLN. INFO.:			NL 1986-50 A	19860113

AB A sustained-release pharmaceutical composition, especially in tablet form, comprises an active component, a C10-15 fatty acid sugar ester, and other appropriate substances. A tablet composition containing ibuprofen (I) 400, dextrose monohydrate 60, polyvidone 18, sucrose monopalmitate 100, stearic acid 1, talc 16, and Mg stearate 5 kg was prepared and pressed into 500,000 tablets giving 24-h release of I. Serum release of an 800 mg dose of I was 2 μg/mL initially and 18

μg/mL after 10 h (peak), and 2 μg/mL after 24 h.
ST ibuprofen controlled release tablet sucrose ester
IT Fatty acids, compounds
RL: BIOL (Biological study)
(C10-15, esters, with sugars, sustained-release tablets containing ibuprofen and)
IT Alcohols, biological studies
Fatty acids, biological studies
RL: BIOL (Biological study)
(C10-25, sustained-release tablets containing ibuprofen and sucrose fatty ester and)
IT Carbohydrates and Sugars, esters
RL: BIOL (Biological study)
(esters, with fatty acids, sustained-release tablets containing ibuprofen and)
IT 57-50-1D, Sucrose, monoesters with fatty acids 26446-38-8, Sucrose monopalmitate
RL: BIOL (Biological study)
(sustained-release tablets containing ibuprofen and)
IT 57-11-4, Stearic acid, biological studies 9003-39-8, Poly(vinyl pyrrolidone)
RL: BIOL (Biological study)
(sustained-release tablets containing ibuprofen and sucrose fatty ester and)
IT 15687-27-1, Ibuprofen
RL: BIOL (Biological study)
(sustained-release tablets containing sucrose fatty ester and)

L1 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1986:632341 CAPLUS
DOCUMENT NUMBER: 105:232341
TITLE: The compressional properties of dextrose monohydrate and anhydrous dextrose of varying water contents
AUTHOR(S): Armstrong, N. Anthony; Patel, Anil; Jones, Trevor M.
CORPORATE SOURCE: Welsh Sch. Pharm., UWIST, Cardiff, UK
SOURCE: Drug Development and Industrial Pharmacy (1986), 12(11-13), 1885-901
CODEN: DDIPD8; ISSN: 0363-9045
DOCUMENT TYPE: Journal
LANGUAGE: English
TI The compressional properties of dextrose monohydrate and anhydrous dextrose of varying water contents
AB The effect of moisture on the compressional properties of anhydrous dextrose [50-99-7] and dextrose monohydrate (I) [14431-43-7] was examined Relations between moisture content and both tablet tensile strength and tablet toughness were evaluated. An increase in the moisture content of anhydrous dextrose produced a corresponding increase in both strength parameters up to the 8.9% moisture level, possibly due to a recrystg. effect. However any further increase in moisture content beyond this point produced a marked reduction in both tablet tensile strength and tablet toughness. For I, any increase in moisture content obtained by exposure to elevated humidities led to a reduction in both tensile strength and toughness. The consolidation of both anhydrous dextrose and I was improved with increasing moisture content, presumably due to a lubrication effect.
ST compression dextrose hydrate; water compression dextrose; tablet

property compression dextrose
IT Tablets
(properties of, moisture content of dextrose effect on)

L1 ANSWER 19 OF 23 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1973:445761 CAPLUS
DOCUMENT NUMBER: 79:45761
TITLE: Comparative evaluation of excipients for direct compression. I
AUTHOR(S): Bolhuis, G. K.; Lerk, C. F.
CORPORATE SOURCE: Lab. Pharm. Technol., State Univ., Groningen, Neth.
SOURCE: Pharmaceutisch Weekblad (1973), 108(22), 469-81
CODEN: PHWEAW; ISSN: 0031-6911
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Micrpocryst. α-cellulose, granular cellulose, microfine cellulose, directly compressible starch, amylose, Ca3(PO4)2.2H2O, dextrose monohydrate, spray-crystallized dextrose, anhydrous lactose, and spray dried lactose were evaluated for tabletting by direct compression. Charactersitics for direct compression at different pressures were the coefficient of variation of upper punch force, the ratio of lower to upper punch force and the ejection force during compression and ejection, % of total energy input immediately recovered as elastic energy, and the weight variation, crushing strength and disintegration time of the compacts formed.
ST excipient tablet direct compression
IT Tablets
(compression of, excipients in relation to)
IT 50-99-7, biological studies 63-42-3 7758-87-4 9004-34-6, biological studies 9005-25-8, biological studies 9005-82-7
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical excipient, compression of, tablet properties in relation to)

L1 ANSWER 20 OF 23 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1970:491229 CAPLUS
DOCUMENT NUMBER: 73:91229
TITLE: Surface area measurements in compressed powder system
AUTHOR(S): Armstrong, Norman Anthony; Griffiths, Ryland V.
CORPORATE SOURCE: Inst. Sci. Technol., Univ. Wales, Cardiff, UK
SOURCE: Pharmaceutica Acta Helvetiae (1970), 45(9), 583-8
CODEN: PAHEAA; ISSN: 0031-6865
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The surface areas of dry and moist compacts of phenacetin (I), paracetamol (II)8 and dextrose monohydrate (III), prepared by compression in a hydraulic press, were determined by N gas adsorption in a continuous-flow system of N and He. As compression pressure is increased in forming the compacts, the surface area rises to a maximum, falls due to bonding between adjacent particles, and then rises again for I and III. Water in the compacts (2.5-6.6%) reduced surface area due to improved lubrication and, for the more soluble II and III, to recrystn. permitting formation of interparticulate bonds.
IT Tablets
(surface area of compressed powder systems for)

L1 ANSWER 21 OF 23 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1969:95610 CAPLUS
DOCUMENT NUMBER: 70:95610
TITLE: Chewing-gum products
INVENTOR(S): Bucher, Robert C.
PATENT ASSIGNEE(S): Fleer, Frank H., Corp.
SOURCE: Ger., 8 pp.
CODEN: GWXXAW
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 1288246		19690130	DE 1964-F44582	19641201
PRIORITY APPLN. INFO.:			US	19631202

AB Dried, finely divided sugar is added to a molten, essentially water-free chewing-gum base, which has been preheated to 77-121°, and mixed till a dry, crumbling, powdery mixture is obtained. The chewing-gum base is used in a proportion of 5-40 weight %. Thus, in a kettle previously heated at 66-82°, the chewing-gum base (12.5%) at 99° is introduced and mixed with aroma substances, coloring material, and 20% of the sugar (in total, 87% dextrose monohydrate (99%), particle size 0.175 mm., is added). After once more adding 20% of the sugar, and mixing, the rest of the sugar is added and mixed. The warm mixture (54-71°) is agitated in a trough. The product floats in water and is not hygroscopic. The product pieces suitable for chewing-gum are coated with sugar and used as chewing-gum; the rest is pulverized to a particle size of 0.833 mm. and pressed in tablets.

L1 ANSWER 22 OF 23 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1967:118865 CAPLUS
DOCUMENT NUMBER: 66:118865
TITLE: Prolonged acting pharmaceutical compositions
INVENTOR(S): Stephenson, Douglas
PATENT ASSIGNEE(S): Wellcome Foundation Ltd.
SOURCE: Brit., 5 pp. Addn. to Brit. 906422
CODEN: BRXXAA
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 1063872		19670330	GB 1962-30868	19631111

AB Addition to Brit. 906,422 (CA 58, 2328g). Tablets for prolonged effect contain a water-soluble drug, a slowly digestible substance, and a hydrophobic waxy binding agent. The core contains procyclidine-HCl (Kemadrin) (I) 2.5, polyethylene glycol 4000 27, and Mg stearate 0.4 mg., to which a middle layer is applied containing I 5.5, hydrogenated castor oil 64, casein 50, and Mg stearate 37 mg., plus an outer layer containing I 2, lactose 118, dextrose monohydrate 70, starch 24.4, and Mg stearate 2.5 mg.

IT Tablets
(sustained-release)

09752899

L1 ANSWER 23 OF 23 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1965:438398 CAPLUS
DOCUMENT NUMBER: 63:38398
ORIGINAL REFERENCE NO.: 63:6800a-c
TITLE: Anthelmintic tablets
INVENTOR(S): Stephenson, Douglas
PATENT ASSIGNEE(S): Wellcome Foundation Ltd.
SOURCE: 6 pp.
DOCUMENT TYPE: Patent
LANGUAGE: Unavailable
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 994742		19650610	GB 1960-31223	19600909

TI Anthelmintic tablets
AB The preparation of tablets containing anthelmintics of the bephenium type, I, as an inner core and piperazine (II) in the outer coating is described. The coating of II may be uniform in thickness, or thicker on one side than on the other, or carry a depression on one face. The method of manufacture is described. A typical tablet contains as inner portion I (R = H, R' = 2-thienyl) p-chlorobenzenesulfonate 216.25, alginic acid 2.165, potato starch 43.25, and Mg stearate 3.25 mg. The coating contains II phosphate 260, lactose 78, dextrose monohydrate or sucrose 78, potato starch 26, and Mg stearate 5.2 mg. The completed tablet of thickness 5.75 mm. and diameter 12.6 mm. contains a hole in one face of diameter 4-6 mm. and depth 1.5-2 mm. The tablets allow controlled release of the anthelmintic components.
IT Anthelmintics
(tablets containing)
IT Ammonium, dimethyl(2-phenoxyethyl)-2-thenyl, p-chlorobenzenesulfonate
(anthelmintic tablet containing)
IT 14538-56-8, Piperazine, phosphate
(anthelmintic tablet containing)

=> d his full

(FILE 'HOME' ENTERED AT 15:48:52 ON 04 OCT 2006)

FILE 'CAPLUS' ENTERED AT 15:49:23 ON 04 OCT 2006
L1 23 SEA ABB=ON PLU=ON TABLET AND DEXTROSE MONOHYDRATE
L2 7 SEA ABB=ON PLU=ON TABLET AND DEXTROSE MONOHYDRATE AND (SOFT OR CHEWABLE)
L3 1 SEA ABB=ON PLU=ON L2 AND FAT
L4 1 SEA ABB=ON PLU=ON L2 AND (OIL OR FAT OR LIPID OR FATTY ADJ ACID)
L5 4 SEA ABB=ON PLU=ON L1 AND (OIL OR FAT OR LIPID OR FATTY ADJ ACID)
L6 19 SEA ABB=ON PLU=ON L1 NOT L5
L7 1 SEA ABB=ON PLU=ON (L1 OR L6) AND FAT FREE
D L5 IBIB KWIC
D L5 IBIB KWIC 1-Y

FILE 'CAPLUS' ENTERED AT 16:15:13 ON 04 OCT 2006

lc

D L1 IBIB KWIC
D L1 IBIB KWIC 1-

FILE HOME

FILE CAPLUS

FILE COVERS 1907 - 4 Oct 2006 VOL 145 ISS 15
FILE LAST UPDATED: 3 Oct 2006 (20061003/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/infopolicy.html

=> d 16 ibib 1-
YOU HAVE REQUESTED DATA FROM 19 ANSWERS - CONTINUE? Y/(N):y

L6 ANSWER 1 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:1885 CAPLUS
DOCUMENT NUMBER: 142:79974
TITLE: Soft tablet containing high molecular weight cellulosics
INVENTOR(S): Wynn, David; Parikh, Nick
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 8 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004265373	A1	20041230	US 2003-608681	20030627
CA 2472432	AA	20041227	CA 2004-2472432	20040625
EP 1498114	A1	20050119	EP 2004-253844	20040625
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
PRIORITY APPLN. INFO.:			US 2003-607766 A	20030627
			US 2003-608681 A	20030627

L6 ANSWER 2 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:993 CAPLUS
DOCUMENT NUMBER: 142:79963
TITLE: Soft tablets containing high molecular

weight celluloses
INVENTOR(S): Wynn, David; Parikh, Nick
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 9 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004265372	A1	20041230	US 2003-607766	20030627
CA 2472432	AA	20041227	CA 2004-2472432	20040625
EP 1491184	A1	20041229	EP 2004-253843	20040625
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				

PRIORITY APPLN. INFO.: US 2003-607766 A 20030627
US 2003-608681 A 20030627

L6 ANSWER 3 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:368929 CAPLUS
DOCUMENT NUMBER: 140:363062
TITLE: Pharmaceutical compositions of ganciclovir
INVENTOR(S): Mathur, Rajeev Shankar; Kumar, Pananchukunnath Manoj; Roy, Sunilendu Bhushan; Malik, Rajiv
PATENT ASSIGNEE(S): Ranbaxy Laboratories Limited, India
SOURCE: PCT Int. Appl., 21 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004037263	A1	20040506	WO 2003-IB4664	20031022
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003274410	A1	20040513	AU 2003-274410	20031022
EP 1556050	A1	20050727	EP 2003-758391	20031022
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
US 2006189565	A1	20060824	US 2006-532024	20060407

PRIORITY APPLN. INFO.: IN 2002-DE1058 A 20021022
WO 2003-IB4664 W 20031022

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:145843 CAPLUS
DOCUMENT NUMBER: 141:355096
TITLE: Powdered and granular materials used in the fabrication of compressed tablets
AUTHOR(S): Delattre, Luc
CORPORATE SOURCE: Laboratoire de Technologie Pharmaceutique, Departement de Pharmacie, Faculte de Medecine, Universite de Liege, Liege, Belg.
SOURCE: Bulletin de la Societe Royale des Sciences de Liege (2003), 72(5), 317-339
CODEN: BSRSA6; ISSN: 0037-9565
PUBLISHER: Societe Royale des Sciences de Liege
DOCUMENT TYPE: Journal
LANGUAGE: French
REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 5 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:737151 CAPLUS
DOCUMENT NUMBER: 139:250306
TITLE: Soft tablets containing high molecular weight polyethylene oxide
INVENTOR(S): Luber, Joseph; Bunick, Frank J.
PATENT ASSIGNEE(S): McNeil-PPC, Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 7 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003175336	A1	20030918	US 2002-97000	20020313
US 6753009	B2	20040622		
CA 2421685	AA	20030913	CA 2003-2421685	20030312
PRIORITY APPLN. INFO.:			US 2002-97000 A	20020313

REFERENCE COUNT: 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 6 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:8105 CAPLUS
DOCUMENT NUMBER: 138:61356
TITLE: Method to aid smoking cessation using dextrose and/or levulose
INVENTOR(S): West, Robert; Hajek, Peter
PATENT ASSIGNEE(S): UK
SOURCE: Brit. UK Pat. Appl., 7 pp.
CODEN: BAXXDU
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

GB 2376885	A1	20021231	GB 2001-15568	20010626
PRIORITY APPLN. INFO.:			GB 2001-15568	20010626

L6 ANSWER 7 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2002:674573 CAPLUS
DOCUMENT NUMBER: 137:206554
TITLE: Chewable tablets containing hydrate excipients.
INVENTOR(S): Bunick, Frank J.; Luber, Joseph
PATENT ASSIGNEE(S): McNeil-PPC, Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 5 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002122822	A1	20020905	US 2000-752601	20001229
US 6814978	B2	20041109		
US 2003175339	A1	20030918	US 2003-413804	20030415
PRIORITY APPLN. INFO.:			US 2000-752601 A1	20001229

REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2001:136959 CAPLUS
DOCUMENT NUMBER: 134:183494
TITLE: Orally dissolvable prenatal multi-vitamin
INVENTOR(S): Devries, Tina; Valentine, William; Valentine, William K.
PATENT ASSIGNEE(S): Warner Chilcott Laboratories Ireland Limited, USA
SOURCE: PCT Int. Appl., 38 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001011991	A1	20010222	WO 2000-US40557	20000803
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6495177	B1	20021217	US 2000-539850	20000331
PRIORITY APPLN. INFO.:			US 1999-148803P P	19990813
			US 1999-148806P P	19990813
			US 2000-539850 A	20000331

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1997:471006 CAPLUS
DOCUMENT NUMBER: 127:152888
TITLE: Potassium carbonate as a desiccant in effervescent tablets
AUTHOR(S): Wells, Mickey L.; Wood, Daniel L.; Sanftleben, Ronald; Shaw, Kelley; Hottovy, Jeff; Weber, Thomas; Geoffroy, Jean-Marie; Alkire, Todd G.; Emptage, Michael R.; Sarabia, Rafael
CORPORATE SOURCE: Glaxo Wellcome Inc., Research Triangle Park, NC, 27709, USA
SOURCE: International Journal of Pharmaceutics (1997), 152(2), 227-235
CODEN: IJPHDE; ISSN: 0378-5173
PUBLISHER: Elsevier
DOCUMENT TYPE: Journal
LANGUAGE: English

L6 ANSWER 10 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1997:204347 CAPLUS
DOCUMENT NUMBER: 126:255506
TITLE: Compressed tablet transitory lubricant system
INVENTOR(S): Valentine, William; Valentine, William K.
PATENT ASSIGNEE(S): Advanced Technology Pharmaceuticals Corporation, USA
SOURCE: U.S., 6 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5609883	A	19970311	US 1994-307922	19940916
PRIORITY APPLN. INFO.:			US 1994-307922	19940916

L6 ANSWER 11 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1996:155953 CAPLUS
DOCUMENT NUMBER: 124:270037
TITLE: Using starch in tabletting
AUTHOR(S): Vanhemelrijk, J.; Heume, M.
CORPORATE SOURCE: Cerestar Euro Centre Food, Vilvoorde, 1800, Belg.
SOURCE: Agro-Food-Industry Hi-Tech (1995), 6(5), 9-10
CODEN: AIHTEI; ISSN: 1120-6012
PUBLISHER: TeknoScienze srl
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English

L6 ANSWER 12 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1995:694438 CAPLUS
DOCUMENT NUMBER: 123:93108
TITLE: Effect of different excipients on release characteristics of acetylsalicylic acid from compressed pellets

09752899

AUTHOR(S): Torrado-Santiago; Torrado, J. J.; Cadorniga, R.
CORPORATE SOURCE: Fac. Pharm., Complutense Univ., Madrid, Spain
SOURCE: Pharmazie (1995), 50(7), 476-8
CODEN: PHARAT; ISSN: 0031-7144
PUBLISHER: Govi-Verlag Pharmazeutischer Verlag
DOCUMENT TYPE: Journal
LANGUAGE: English

L6 ANSWER 13 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1993:678520 CAPLUS
DOCUMENT NUMBER: 119:278520
TITLE: "In vitro" drug release of AAS matrix tablets
AUTHOR(S): Torrado, S.; Torrado, Susana; Torrado V., J.; Cadorniga, R.
CORPORATE SOURCE: Univ. Complutense, Madrid, 28040, Spain
SOURCE: Proc. Int. Symp. Controlled Release Bioact. Mater., 20th (1993), 370-1. Editor(s): Roseman, Theodore J.; Peppas, Nicholas A.; Gabelnick, Henry L. Controlled Release Soc.: Deerfield, Ill.
CODEN: 59LOAL
DOCUMENT TYPE: Conference
LANGUAGE: English

L6 ANSWER 14 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1988:479708 CAPLUS
DOCUMENT NUMBER: 109:79708
TITLE: Sustained-release pharmaceutical containing fatty acid sugar esters as excipients
INVENTOR(S): Jansen, Frans Herwigjan; Hendrickx, Jean
PATENT ASSIGNEE(S): Sanico, N. V., Belg.; N. V. Gantax S. A.
SOURCE: Eur. Pat. Appl., 13 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 230332	A1	19870729	EP 1987-200031	19870112
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
NL 8600050	A	19870803	NL 1986-50	19860113
FI 8700092	A	19870714	FI 1987-92	19870112
NO 8700104	A	19870714	NO 1987-104	19870112
DK 8700161	A	19870714	DK 1987-161	19870113
ZA 8700216	A	19870826	ZA 1987-216	19870113
JP 62209025	A2	19870914	JP 1987-7403	19870113
PRIORITY APPLN. INFO.:			NL 1986-50 A	19860113

L6 ANSWER 15 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1986:632341 CAPLUS
DOCUMENT NUMBER: 105:232341
TITLE: The compressional properties of dextrose monohydrate and anhydrous dextrose of varying water contents
AUTHOR(S): Armstrong, N. Anthony; Patel, Anil; Jones, Trevor M.
CORPORATE SOURCE: Welsh Sch. Pharm., UWIST, Cardiff, UK

09752899

SOURCE: Drug Development and Industrial Pharmacy (1986), 12(11-13), 1885-901
CODEN: DDIPD8; ISSN: 0363-9045
DOCUMENT TYPE: Journal
LANGUAGE: English

L6 ANSWER 16 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1973:445761 CAPLUS
DOCUMENT NUMBER: 79:45761
TITLE: Comparative evaluation of excipients for direct compression. I
AUTHOR(S): Bolhuis, G. K.; Lerk, C. F.
CORPORATE SOURCE: Lab. Pharm. Technol., State Univ., Groningen, Neth.
SOURCE: Pharmaceutisch Weekblad (1973), 108(22), 469-81
CODEN: PHWEAW; ISSN: 0031-6911
DOCUMENT TYPE: Journal
LANGUAGE: English

L6 ANSWER 17 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1970:491229 CAPLUS
DOCUMENT NUMBER: 73:91229
TITLE: Surface area measurements in compressed powder system
AUTHOR(S): Armstrong, Norman Anthony; Griffiths, Ryland V.
CORPORATE SOURCE: Inst. Sci. Technol., Univ. Wales, Cardiff, UK
SOURCE: Pharmaceutica Acta Helvetiae (1970), 45(9), 583-8
CODEN: PAHEAA; ISSN: 0031-6865
DOCUMENT TYPE: Journal
LANGUAGE: English

L6 ANSWER 18 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1969:95610 CAPLUS
DOCUMENT NUMBER: 70:95610
TITLE: Chewing-gum products
INVENTOR(S): Bucher, Robert C.
PATENT ASSIGNEE(S): Fleer, Frank H., Corp.
SOURCE: Ger., 8 pp.
CODEN: GWXXAW
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 1288246		19690130	DE 1964-F44582	19641201
PRIORITY APPLN. INFO.:			US	19631202

L6 ANSWER 19 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1965:438398 CAPLUS
DOCUMENT NUMBER: 63:38398
ORIGINAL REFERENCE NO.: 63:6800a-c
TITLE: Anthelmintic tablets
INVENTOR(S): Stephenson, Douglas
PATENT ASSIGNEE(S): Wellcome Foundation Ltd.
SOURCE: 6 pp.
DOCUMENT TYPE: Patent
LANGUAGE: Unavailable

lc

09752899

FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 994742		19650610	GB 1960-31223	19600909

=> d his full

(FILE 'HOME' ENTERED AT 15:48:52 ON 04 OCT 2006)

FILE 'CAPLUS' ENTERED AT 15:49:23 ON 04 OCT 2006

L1 23 SEA ABB=ON PLU=ON TABLET AND DEXTROSE MONOHYDRATE
L2 7 SEA ABB=ON PLU=ON TABLET AND DEXTROSE MONOHYDRATE AND (SOFT OR CHEWABLE)
L3 1 SEA ABB=ON PLU=ON L2 AND FAT
L4 1 SEA ABB=ON PLU=ON L2 AND (OIL OR FAT OR LIPID OR FATTY ADJ ACID)
L5 4 SEA ABB=ON PLU=ON L1 AND (OIL OR FAT OR LIPID OR FATTY ADJ ACID)
L6 19 SEA ABB=ON PLU=ON L1 NOT L5
L7 1 SEA ABB=ON PLU=ON (L1 OR L6) AND FAT FREE
D L5 IBIB KWIC
D L5 IBIB KWIC 1-Y

lc